Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 78Leukemia, Lymphocytic, Chronic, B-Cell 77Leukemia 77Myelodysplastic Syndromes 61Lymphoma 51Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Multiple Myeloma 46Lymphoma, Non-Hodgkin 45Hodgkin Disease 36Leukemia, Myelogenous, Chronic, BCR-ABL Positive 31Hematologic Neoplasms 27Melanoma 26Recurrence 20Lymphoma, Follicular 18Lymphoma, Mantle-Cell 17Myeloproliferative Disorders 16Graft vs Host Disease 15Primary Myelofibrosis 14Lymphoma, Large B-Cell, Diffuse 14Lymphoma, B-Cell 13Neoplasms, Plasma Cell 12Lymphoma, B-Cell, Marginal Zone 11Leukemia, Myelomonocytic, Chronic 10Anemia, Aplastic 10Neoplasms 9Hematologic Diseases 9Neoplasm Metastasis 8Blast Crisis 8Anemia, Refractory, with Excess of Blasts 8Ovarian Neoplasms 7

Interventions

Cisplatin 30Pemetrexed 21Gemcitabine 11Radiotherapy 6Nivolumab 6Drug Therapy 6Cyclophosphamide 6Carboplatin 6durvalumab 4Vinorelbine 4Chemotherapy, Adjuvant 4tumor necrosis factor-alpha, CNGRC fusion protein, human 3sodium thiosulfate 3sargramostim 3Ipilimumab 3Doxorubicin 3raltitrexed 2pembrolizumab 2cediranib 2SS1(dsFv)PE38 2Radiotherapy, Intensity-Modulated 2Psychiatric Rehabilitation 2Photochemotherapy 2Neoadjuvant Therapy 2Methotrexate 2Interferon-alpha 2Imatinib Mesylate 2Granulocyte-Macrophage Colony-Stimulating Factor 2Gefitinib 2Everolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Mesothelioma, Malignant × fludarabine × Clear all
NCT02414945 2023-01-10

TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

University Health Network, Toronto

Phase 1/2 Completed
9 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡